$0.01
(Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
5 Years Aggregate
CFO
$-242.71 Mln
EBITDA
$-389.78 Mln
Net Profit
$-345.11 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ProKidney Corp (PROK)
| -18.3 | 18.8 | 1.1 | -26.5 | -40.1 | -- | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
ProKidney Corp (PROK)
| 32.5 | -5.0 | -74.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout ProKidney Corp (PROK)
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal... cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Read more
-
Founder
Dr. Timothy A. Bertram D.V.M., Ph.D.
-
Founder
Dr. Timothy A. Bertram D.V.M., Ph.D.
-
Headquarters
Winston-Salem, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for ProKidney Corp (PROK)
What is the current share price of ProKidney Corp (PROK) Today?
The share price of ProKidney Corp (PROK) is $1.83 (NASDAQ) as of 28-Aug-2026 16:00 EDT. ProKidney Corp (PROK) has given a return of -40.09% in the last 3 years.
What is the current PB & PE ratio of ProKidney Corp (PROK)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-4.56 |
-0.31 |
2024 |
-3.54 |
-0.22 |
2023 |
-3.01 |
-0.10 |
2022 |
-3.91 |
-0.38 |
2021 |
-- |
-- |
What is the 52 Week High and Low of ProKidney Corp (PROK)?
The 52-week high and low of ProKidney Corp (PROK) are Rs 3.48 and Rs 1.30 as of 31-Aug-2026.
What is the market cap of ProKidney Corp (PROK)?
ProKidney Corp (PROK) has a market capitalisation of $ 731 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in ProKidney Corp (PROK)?
Before investing in ProKidney Corp (PROK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.